On the face of it, Connetics Corp.'s decision to enlist MGI Pharma Inc. (MOGN) to promote both of CNCT's products to the U.S. rheumatology market looks like a departure from CNCT's strategy of in-licensing late-stage niche products and taking them to market on its own.

Under last week's deal, MOGN's 24-person sales force will sell both Luxiq betamethasone corticosteroid to treat scalp dermatoses and Ridaura gold salt to treat rheumatoid arthritis.

MOGN's reps already